OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Woyach on Responses to Pirtobrutinib in CLL/SLL With/Without Prior BCL2 Inhibitor Exposure

December 15th 2023

Jennifer A Woyach, MD, discusses the efficacy of pirtobrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who progressed on treatment with a covalent BTK inhibitor, including subgroups with or without previous exposure to a BCL2 inhibitor.

Dr Bardia on the Efficacy and Safety of Dato-DXd in HR+/HER2– Breast Cancer

December 15th 2023

Aditya Bardia, MD, MPH, discusses key efficacy results from the phase 3 TROPION-Breast01 trial of datopotamab deruxtecan in hormone receptor–positive, HER2-negative breast cancer.

Dr Tolaney on the Real-World Efficacy of T-DXd in HER2+ or HER2-Low Breast Cancer

December 15th 2023

Sara M. Tolaney, MD, MPH, discusses the real-world efficacy of fam-trastuzumab deruxtecan in patients with HER2-positive or HER2-low metastatic breast cancer, including patients who experienced changes in HER2 status during the treatment course.

Dr Matous on the Use Talquetamab/Pomalidomide in Relapsed/Refractory Multiple Myeloma

December 12th 2023

Jeffrey Matous, MD, discusses outcomes from the phase 1b MonumenTAL-2 trial with the combination of talquetamab and pomalidomide in patients with relapsed/refractory multiple myeloma.

Dr Cohen on the Efficacy of Pirtobrutinib in High-Risk Patients With MCL

December 12th 2023

Jonathon B. Cohen, MD, MS, discusses safety and efficacy outcomes with pirtobrutinib in previously treated patients with relapsed/refractory mantle cell lymphoma, as observed in the phase 1/2 BRUIN study.

Dr Andorsky on Real-World Treatment Patterns With BTK Inhibitors in CLL/SLL

December 12th 2023

David J. Andorsky, MD, discusses recently observed patterns of care with BTK inhibitors in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in the community setting in the United States, and how social determinants of health may have affected these outcomes.

Dr Rampal on Findings From the MANIFEST-2 Trial in JAK Inhibitor–Naive Myelofibrosis

December 12th 2023

Raajit K. Rampal, MD, PhD, discusses findings from the phase 3 MANIFEST-2 trial investigating pelabresib in combination with ruxolitinib for JAK inhibitor–naive patients with myelofibrosis.

Dr Gholam on Camrelizumab Plus Rivoceranib in Unresectable HCC

December 11th 2023

Pierre Gholam, MD, discusses findings from the phase 3 CARES-310 trial of camrelizumab plus rivoceranib in patients with unresectable hepatocellular carcinoma.

Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma

December 10th 2023

Susan Bal, MD, discusses updated safety and efficacy data from a phase 1 study evaluating the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, including in patients with prior BCMA-directed therapy.

Dr Ghia on a Biomarker Analysis of the SEQUOIA Trial in CLL/SLL

December 10th 2023

Paolo Ghia, MD, PhD, full professor, discusses a biomarker subgroup analysis of the phase 3 SEQUOIA trial investigating zanubrutinib vs bendamustine plus rituximab in patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without 17p deletions.

Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL

December 10th 2023

Michael R. Cook, MD, discusses real-world data associated with the utilization of bridging therapy prior to treatment with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.

Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL

December 10th 2023

Andre Goy, MD, discusses outcomes with brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma enrolled in the phase 2 ZUMA-2 trial and the expanded access ZUMA-18 study.

Dr Schmid on the Use of Perioperative Pembrolizumab in TNBC

December 8th 2023

Peter Schmid, MD, PhD, discusses updated event-free survival findings from the phase 3 KEYNOTE-522 trial of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in patients with early-stage triple-negative breast cancer.

Dr Khan on Optimizing Local Therapy Using MRI and a 12-Gene Expression Assay in DCIS

December 8th 2023

Seema A. Khan, MD, discusses 5-year clinical outcomes from the ECOG-ACRIN E4112 trial, which is evaluating the use of MRI and a 12-gene expression assay to optimize local therapy for patients with ductal carcinoma in situ.

Dr O'Cearbhaill on Results With Ubamatamab Plus Cemiplimab in Recurrent Ovarian Cancer

December 8th 2023

Roisin E. O'Cearbhaill, MD, discusses key findings from a phase 1/2 dose escalation study of ubamatamab plus cemiplimab in recurrent ovarian cancer.

Dr Freedland on the FDA Approval of Enzalutamide in nmCSPC

December 8th 2023

Stephen J. Freedland, MD, discusses the significance of the FDA approval of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

Dr Kadia on Targeting the IRAK4 Pathway in AML

December 8th 2023

Tapan M. Kadia, MD, discusses targeting the IRAK4 pathway in patients with acute myeloid leukemia and highlights the importance of utilizing targeted therapies in the treatment of patients with hematologic malignancies.

Dr Tolaney on Sequencing Available ADCs in Breast Cancer

December 8th 2023

Sara M. Tolaney, MD, MPH, discusses the current utilization of antibody-drug conjugates in patients with hormone receptor-positive, HER2-negative breast cancer, highlighting the question of sequencing among available agents.

Dr Cortés on Analyzing Outcomes With T-DXd in HER2+ Breast Cancer With Brain Metastases

December 7th 2023

Javier Cortés, MD, PhD, discusses the rationale for analyzing outcomes with trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer who have brain metastases.

Dr Graff on the Relation Between ctDNA Positivity and Disease Recurrence in HR+/HER2– Breast Cancer

December 7th 2023

Stephanie L. Graff, MD, discusses findings from a pilot study exploring the association between disease recurrence and circulating tumor DNA positivity in patients with hormone receptor–positive, HER2-negative, node-positive, high-risk, early breast cancer who have received adjuvant treatment of abemaciclib and endocrine therapy.